Catalent (NYSE:CTLT) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

Other analysts have also issued research reports about the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, February 20th. UBS Group reissued a “neutral” rating and issued a $63.50 price objective (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Barclays upped their target price on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. Finally, Stephens reaffirmed an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $53.14.

Catalent Trading Up 0.0 %

Shares of CTLT opened at $54.97 on Tuesday. Catalent has a twelve month low of $31.80 and a twelve month high of $60.20. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The company’s fifty day simple moving average is $56.09 and its 200-day simple moving average is $50.55. The company has a market cap of $9.95 billion, a P/E ratio of -9.01, a P/E/G ratio of 6.64 and a beta of 1.18.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. As a group, analysts expect that Catalent will post 0.28 EPS for the current year.

Institutional Investors Weigh In On Catalent

Institutional investors have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC boosted its position in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares in the last quarter. Czech National Bank grew its stake in shares of Catalent by 0.7% during the first quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after acquiring an additional 228 shares during the last quarter. BNP Paribas Asset Management Holding S.A. increased its holdings in shares of Catalent by 1.9% during the fourth quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock valued at $802,000 after acquiring an additional 328 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Catalent by 6.2% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after purchasing an additional 331 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Catalent by 2.6% in the 3rd quarter. Teacher Retirement System of Texas now owns 13,966 shares of the company’s stock worth $636,000 after purchasing an additional 350 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.